|
Mar 18
|
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
|
Mar 4
|
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
|
|
Feb 27
|
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
|
|
Feb 23
|
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
|
|
Feb 2
|
New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT
|
|
Feb 1
|
New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT
|
|
Dec 11
|
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
|
|
Dec 8
|
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT
|
|
Dec 7
|
New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT
|
|
Dec 1
|
New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT
|
|
Nov 17
|
New to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PT
|
|
Nov 15
|
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript
|
|
Nov 14
|
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
|
|
Nov 2
|
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
|
|
Apr 22
|
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
|